Granted Patent
B2
US 12,195,455 · App. 17/269,811 · Granted Jan 14, 2025
Succinate and fumarate acid addition salts of piperazine derivatives
Inventors:
Anna Quattropani (Rolle, CH); Santosh S. Kulkarni (Bangalore, IN); Awadut Gajendra Giri (Bangalore, IN); Robert Hett (Muttenz, CH); David Malcolm Crowe (Reading, GB)
Assignee:
Asceneuron SA
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to succinic acid addition salts or fumaric acid addition salts of piperazine derivatives of formula (I), as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
Claims (4)
1. A mono-succinic acid salt of compound Ia,
wherein the salt is in a solid form having the characteristic X-ray powder diffraction pattern as shown on FIG. 1 .
2. A mono-fumaric acid salt of compound Ia,
wherein the salt is in a solid form having the characteristic X-ray powder diffraction pattern as shown on FIG. 4 .
Assignments (3)
RELEASE OF SECURITY INTEREST
Recorded Feb 19, 2025
From: KREOS CAPITAL VI (UK) LIMITED
To: ASCENEURON SA
Reel/Frame 070252/0165 →
SECURITY INTEREST
Recorded Mar 22, 2022
From: ASCENEURON SA
To: KREOS CAPITAL VI (UK) LIMITED
Reel/Frame 059337/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 26, 2021
From: QUATTROPANI, ANNA; KULKARNI, SANTOSH S.; GIRI, AWADUT GAJENDRA; HETT, ROBERT; CROWE, DAVID MALCOLM
To: ASCENEURON SA
Reel/Frame 055735/0939 →
Priority Claims (1)
EP 18190155
· Aug 22, 2018
· regional
Continuity (1)
References Cited (289)
US 3299067A
· Gilbert et al.
· 1967
[cited by applicant]
US 3457263A
· Regnier et al.
· 1969
[cited by applicant]
US 3485757A
· Shapiro
· 1969
[cited by applicant]
US 3489757A
· Koppe et al.
· 1970
[cited by applicant]
US 4600025A
· Grigg et al.
· 1986
[cited by applicant]
US 5935974A
· Rae et al.
· 1999
[cited by applicant]
US 7582769B2
· Murray et al.
· 2009
[cited by applicant]
US 7666875B2
· Gallagher, Jr. et al.
· 2010
[cited by applicant]
US 8008326B2
· Borza et al.
· 2011
[cited by applicant]
US 8952166B2
· Ding et al.
· 2015
[cited by applicant]
US 9120781B2
· Li et al.
· 2015
[cited by applicant]
US 20070027328A1
· Aronhime et al.
· 2007
[cited by applicant]
US 20080300276A1
· Borza et al.
· 2008
[cited by applicant]
US 20100022517A1
· Richards et al.
· 2010
[cited by applicant]
US 20110053982A1
· Fay et al.
· 2011
[cited by applicant]
US 20110060012A1
· Meyers et al.
· 2011
[cited by applicant]
US 20220143042A1
· Quattropani et al.
· 2022
[cited by applicant]
CN 1791594A
· 2006
[cited by applicant]
CN 103435606
· 2013
[cited by applicant]
EP 2301936
· 2011
[cited by applicant]
EP 2687507
· 2014
[cited by applicant]
FR 1311316
· 1962
[cited by applicant]
JP 2010270034
· 2010
[cited by applicant]
WO WO1993021181
· 1993
[cited by applicant]
WO WO1997043279
· 1997
[cited by applicant]
WO WO1998046590
· 1998
[cited by applicant]
WO WO9921850
· 1999
[cited by applicant]
WO WO02094799
· 2002
[cited by applicant]
WO WO2003092678
· 2003
[cited by applicant]
WO WO2004002481
· 2004
[cited by applicant]
WO WO2004005293
· 2004
[cited by applicant]
WO WO2004022558
· 2004
[cited by applicant]
WO WO2004094380
· 2004
[cited by applicant]
WO WO2005110982
· 2005
[cited by applicant]
WO WO2006092049
· 2006
[cited by applicant]
WO WO2007008541A2
· 2007
[cited by applicant]
WO WO2007115077
· 2007
[cited by applicant]
WO WO2007135398
· 2007
[cited by applicant]
WO WO2007146122
· 2007
[cited by applicant]
WO WO2008012623
· 2008
[cited by applicant]
WO WO2008025170
· 2008
[cited by applicant]
WO WO2009011904
· 2009
[cited by applicant]
WO WO2009053373
· 2009
[cited by applicant]
WO WO2009131926
· 2009
[cited by applicant]
WO WO2010018868
· 2010
[cited by applicant]
WO WO2010021381
· 2010
[cited by applicant]
WO WO2010022517
· 2010
[cited by applicant]
WO WO2010026989
· 2010
[cited by applicant]
WO WO2010089127
· 2010
[cited by applicant]
WO WO2010101949
· 2010
[cited by applicant]
WO WO2010108115
· 2010
[cited by applicant]
WO WO2010108268
· 2010
[cited by applicant]
WO WO2010151318
· 2010
[cited by applicant]
WO WO2011140640
· 2011
[cited by applicant]
WO WO2012037298
· 2012
[cited by applicant]
WO WO2012061927
· 2012
[cited by applicant]
WO WO2012062157
· 2012
[cited by applicant]
WO WO2012062759
· 2012
[cited by applicant]
WO WO2012083435
· 2012
[cited by applicant]
WO WO2012117219
· 2012
[cited by applicant]
WO WO2013028715
· 2013
[cited by applicant]
WO WO2013066729
· 2013
[cited by applicant]
WO WO2014023723
· 2014
[cited by applicant]
WO WO2014032187
· 2014
[cited by applicant]
WO WO2014159234
· 2014
[cited by applicant]
WO WO2015083028
· 2015
[cited by applicant]
WO WO2015128333
· 2015
[cited by applicant]
WO WO2015164508
· 2015
[cited by applicant]
WO WO2016030443
· 2016
[cited by applicant]
WO WO2017001660
· 2017
[cited by applicant]
WO WO2017076900
· 2017
[cited by applicant]
WO WO2017087858
· 2017
[cited by applicant]
WO WO2017087863
· 2017
[cited by applicant]
WO WO2017091818
· 2017
[cited by applicant]
WO WO2017106254
· 2017
[cited by applicant]
WO WO2017144633
· 2017
[cited by applicant]
WO WO2017144635
· 2017
[cited by applicant]
WO WO2017144637
· 2017
[cited by applicant]
WO WO2017144639
· 2017
[cited by applicant]
WO WO2017144639A1
· 2017
[cited by examiner]
WO WO2017223243
· 2017
[cited by applicant]
WO WO2018026371
· 2018
[cited by applicant]
WO WO2018109198
· 2018
[cited by applicant]
WO WO2018109202
· 2018
[cited by applicant]
WO WO2018140299
· 2018
[cited by applicant]
WO WO2018141984
· 2018
[cited by applicant]
WO WO2018153507
· 2018
[cited by applicant]
WO WO2018153508
· 2018
[cited by applicant]
WO WO2018154133
· 2018
[cited by applicant]
WO WO2018153508A2
· 2018
[cited by examiner]
WO WO2018217558
· 2018
[cited by applicant]
WO WO2020039027
· 2020
[cited by applicant]
WO WO2020039028
· 2020
[cited by applicant]
WO WO2020039029
· 2020
[cited by applicant]
WO WO2020169804
· 2020
[cited by applicant]
Berge et al. Pharmaceutical Salts, Journal of Pharmaceutical Sciences, 66, p. 1-19. (Year: 1977).
[cited by examiner]
Bastin et al. Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities (Organic Process Research & Development, 4, p. 427-435). (Year: 2000).
[cited by examiner]
Smith, P.W. et al “New spiropiperidines as potent and selective non-peptide tachykinin NK
[cited by applicant]
“Acute Leukemia”, Merck Manual (Online Edition), Hematology and Oncology, 6 pages, pp. 1-6, 2013.
[cited by applicant]
Damasio, “Alzheimer's Disease and related dementias”, Cecil Textbook of Medicine, 20th Edition, vol. 2, Edited by Bennett and Plum, pp. 1992-1996, 1996.
[cited by applicant]
Gura, “Cancer Models: Systems for identifying new drugs are often faulty”, Science, vol. 278, pp. 1041-1042, 1997 (5 pages).
[cited by applicant]
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials”, British Journal of Cancer, vol. 84, No. 10, pp. 1424-1431, 2001.
[cited by applicant]
Layzer, “Degenerative diseases of the nervous system”, Cecil Textbook of Medicine, 20th Edition, Section Five, vol. 2, Edited by Bennett and Plum, pp. 2050-2057, 1996.
[cited by applicant]
Pearce et al. “Failure modes in anticancer drug discovery and development”, Cancer Drug Design and Discovery Edited by Stephen Neidle, Chapter 18, pp. 424-435, 2008.
[cited by applicant]
Simone “Oncology: Introduction”, Cecil Textbook of Medicine, 20th Edition, vol. 1, Edited by Bennett and Plum, pp. 1004-1010, 1996.
[cited by applicant]
Abdel-Magid, A. F. et al. “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures” J. Org. Chem., (1996), 61, pp. 3849-3862.
[cited by applicant]
Albertson, N. F. “Alkylation with Non-ketonic Mannich Bases. Aminothiazoles and Pyrrole” J. Am. Chem. Soc., 1948, 70(2), 669-670.
[cited by applicant]
Andres, J. I. et al. “Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging” J. Med.…
[cited by applicant]
Ansari et al. “The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration”, Frontiers in Neuroscience, 2019, vol. 13, Article 473, 9 pages.
[cited by applicant]
Aitipamula, S. et al. “Polymorphs, Salts, and Cocrystals: What's in a Name?”, Crystal Growth & Design, 12(5), 2012, p. 2147-2152.
[cited by applicant]
Apsunde, T.D. et al. “Microwave-Assisted Iridium-Catalyzed Synthesis of Nicotine and Anabasine Derivatives”, Synthesis, vol. 45, No. 15, 2013, pp. 2120-2124.
[cited by applicant]
Aube, J. et al. “Intramolecular Schmidt reaction of alkyl azides”, J. Am. Chem. Soc. 1991, vol. 113, No. 23, p. 8965-8966.
[cited by applicant]
Augustine, J. K. et al. “Propylphosphonic anhydride (T3P®): an efficient reagent for the one-pot synthesis of 1,2,4-oxadiazoles, 1,3,4-oxadiazoles, and 1,3,4-thiadiazoles” Tetrahedron, (2009), 65, pp. 9989-9996.
[cited by applicant]
Bastin, R. J. et al. “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, Organic Process Research & Development, 2000, 4, 427-435.
[cited by applicant]
Berge, S. M. et al. “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 1977, 66(1), 1-19.
[cited by applicant]
Biscoe, M. R. et al. “A New Class of Easily Activated Palladium Precatalysts for Facile C-N Cross-Coupling Reactions and Low Temperature Oxidative Addition of Aryl Chlorides”, J. Am. Chem. Soc., 2008, 130, 6686-6687.
[cited by applicant]
Bohnert, T. et al. “Plasma Protein Binding: From Discovery to Development”, J. Pharmaceutical Sciences, 2013, 102, 2953-2994.
[cited by applicant]
Bras, N. F. et al. “Glycosidase inhibitors: a patent review (2008-2013)” Expert Opinion on Therapeutic Patents, vol. 24, No. 8, 2014, pp. 857-874.
[cited by applicant]
Bundgaard, H. “Design and Application of Prodrugs”, from a Textbook of Drug Design and Development Chapter 5, Harwood Academic Publishers, 1991, 113-191.
[cited by applicant]
Bundgaard, H. “Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities”, Design of Prodrugs, (1985), 1 page.
[cited by applicant]
Calcagno, A. M. “Comparison of Drug Transporter Levels in Normal Colon, Colon Cancer, and Caco-2 Cells: Impact on Drug Disposition and Discovery”, Mol. Pharm., 2006, 3(1), 87-93.
[cited by applicant]
CAS Registry (Online) Nos. 948053-91-6; 540512-02-5; 697229-62-2; 346662-52-0; 345992-64-5 (STN database summary sheets) Sep. 26, 2007.
[cited by applicant]
“Chemical Encyclopedia”, vol. 4, pp. 990-993, 1988. (Machine translation attached).
[cited by applicant]
Chen, Y. et al. “Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structurebased virtual screening”, RSC Advances, 2017, 7(6), 3429-3438.
[cited by applicant]
Chen W. et al. “Redox-Neutral [alpha]-Arylation of Amines”, Organic Letters, vol. 16, No. 3, 2014, pp. 730-732.
[cited by applicant]
Chrovian, C. C. et al. “A Dipolar Cycloaddition Reaction to Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical C…
[cited by applicant]
Collet, A. “Resolution of Racemates: Did you say ‘Classical?’”, Angewandte Chemie International Edition, 1998, 37(23), 3239-3241.
[cited by applicant]
Dai, W. et al. “Highly Chemoselective and Enantioselective Catalytic Oxidation of Heteroaromatic Sulfides via High-Valent Manganese(IV)-Oxo Cation Radical Oxidizing Intermediates”, ACS Catalysis, 2017, vol. 7, p. 4890-4…
[cited by applicant]
Dassanayaka, S. and Jones, S. “O-GlcNAc and the cardiovascular system”, Pharmacology & Therapeutics, 2014, 142, 62-71.
[cited by applicant]
Database registry (online) Chemical abstract service, Columbus, Ohio, US; Dec. 6, 2011, “Piperazine, 1-[1-(1,3-benzodioxol-5-yl)ethyl]-4-(5-bromo-6-methoxy-2-pyridinyl)-”, Database accession No. 1349611-60-4.
[cited by applicant]
Database Pubchem Compound (Online) NCBI; Jan. 24, 2012, XP002768130, Database accession No. CID 54914491.
[cited by applicant]
Database PubChem Compound (Online) NCBI; May 28, 2009; XP002768131, Database accession No. CID 28798635.
[cited by applicant]
Database PubChem Compound, NCBI; 9. Apr. 2016; XP002768133, Database accession No. CID 118902929.
[cited by applicant]
Database Registry, Chemical Abstracts Service, 2016, CID120907609, 10 pages.
[cited by applicant]
Database Registry, Chemical Abstracts Service, Jan. 11, 2017, XP002768132, Database accession No. 2055841-81-9.
[cited by applicant]
Dorfmueller, H. C. et al. “Cell-Penetrant, Nanomolar O-GlcNAcase Inhibitors Selective against Lysosomal Hexosaminidases”, Chem. Biol., 2010, 17, 1250-1255.
[cited by applicant]
Dubois, B. et al. “Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria”, Alzheimers Dement., 2016, 12, 292-323.
[cited by applicant]
Dubois, B. et al. “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria”, Lancet Neurol., 2014, 13, 614-629.
[cited by applicant]
Dyatkin, A. B. et al. “Determination of the Absolute Configuration of a Key Tricyclic Component of a Novel Vasopressin Receptor Antagonist by Use of Vibrational Circular Dichroism”, Chirality, 2002, 14, 215-219.
[cited by applicant]
Ellman, J. A. et al. “N-tert-Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines” Acc. Chem. Res. (2002), 35, pp. 984-995.
[cited by applicant]
Fleury-Bregeot et al. “Suzuki-Miyaura Cross-Coupling of Potassium Alkoxyethyltri-fluoroborates: Access to Aryl/Heteroarylethyloxy Motifs”, J. Org. Chem. 2012, vol. 77, No. 22, p. 10399-10408.
[cited by applicant]
Fors, B. P. et al. “A Highly Active Catalyst for Pd-Catalyzed Amination Reactions: Cross-Coupling Reactions Using Aryl Mesylates and the Highly Selective Monoarylation of Primary Amines Using Aryl Chlorides”, J. Am. Che…
[cited by applicant]
Frehel, D. et al. “New synthesis of 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine”, Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 1011-1016.
[cited by applicant]
Frings, M. et al. “Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery”, European Journal of Medicinal Chemistry, 2017, 126, 225-245.
[cited by applicant]
Goho, A. “Tricky Business”, Science News, 2004, 166(8), 122-124.
[cited by applicant]
Gong et al. “O-GlcNAcylation: A regulator of tau pathology and neurodegeneration”, Alzheimer's & Dementia, 2016, vol. 12, p. 1078-1089.
[cited by applicant]
Golub, T. R. et al. “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”, Science, 1999, 286, 531-537.
[cited by applicant]
Gould, P. L. “Salt selection for basic drugs”, International Journal of Pharmaceutics, 1986, 33, 201-217.
[cited by applicant]
Graham, D. L. et al. “Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy”, Neuropharmacology, 2014, 79, 307-313.
[cited by applicant]
Gujjar, R. et al. “Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice”, J. Med. Chem., 2011, 54 (11),…
[cited by applicant]
Haleblian, J.; McCrone, W. “Pharmaceutical Applications of Polymorphism”, J. Pharm. Sci., 1969, 58(8), 911-929.
[cited by applicant]
Haleblian, J. “Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications”, J. Pharm. Sci., 1975, 64(8), 1269-1288.
[cited by applicant]
Hemming, K. “Product Class 6: 1,2,4-Oxadizoles” Science of Synthesis, (2004), 13(6), pp. 127-184.
[cited by applicant]
Hulikal, V. “Deuterium Labeled Compounds in Drug Discovery Process”, Abstract, Bioorganics ond Applied Materials Pvt Ltd. (2010), 1 page.
[cited by applicant]
Jakopin, Z. et al. “Recent Advances in the Synthesis of 1,2,4- and 1,3,4-Oxadiazoles” Current Organic Chemistry, (2008), 12(10), pp. 850-898.
[cited by applicant]
Kempson, J. “Name Reactions in Heterocyclic Chemistry II” John Wiley & Sons. Eds. Jie Jack Li and E. J. Corey, (2011), pp. 299-308.
[cited by applicant]
Kim, E. J. et al. “Enzymatic characterization of O-GlcNAcase isoforms using a fluorogenic GlcNAc substrate”, Carbohydrate Research, 2006, 341(8), p. 971-982.
[cited by applicant]
Kim, E. J. “Chemical Arsenal for the Study of O-GlcNAc”, Molecules, 2011, vol. 16, p. 1987-2022.
[cited by applicant]
Kim et al. “Discovery of β-Arrestin Biased Ligands of 5-HT
[cited by applicant]
Knapp, S. et al. “An Allosamizoline/ Glucosamine Hybrid NAGase Inhibitor”, Synlett, 1997, 5, 435-436.
[cited by applicant]
Lefebvre, T. “Recall sugars, forget Alzheimer's”, Nature Chemical Biology, 2012, 8(4), 325-326.
[cited by applicant]
Legros, J. et al. “Applications of Catalytic Asymmetric Sulfide Oxidations to the Syntheses of Biologically Active Sulfoxides”, Adv. Synth. Catal., 2005, 347, 19-31.
[cited by applicant]
Liu, X. et al. “Rational Use of Plasma Protein and Tissue Binding Data in Drug Design”, J. Med. Chem. 2014, 57, 8238-8248.
[cited by applicant]
Marwaha, A. et al. “Bioisosteric Transformations and Permutations in the Triazolopyrimidine Scaffold to Identify the Minimum Pharmacophore Required for Inhibitory Activity against Plasmodium falciparum Dihydroorotate De…
[cited by applicant]
Mariappa, D. et al. “A mutant O-GlcNAcase as a probe to reveal global dynamics of the
[cited by applicant]
Marotta, N. P. et al., “O-GlcNAc modification blocks the aggregation and toxicity of the Parkinson's disease associated protein α-synuclein”, Nat. Chem, 2015, 7(11), 913-920.
[cited by applicant]
Masuda, N. et al. “Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides”, Bioorg. Med. Chem., 2004, 12, 6171-6182.
[cited by applicant]
Merchant, R. R. et al. “Regioselective Preparation of Saturated Spirocyclic and Ring-Expanded Fused Pyrazoles”, J. Org. Chem. 2014, vol. 79, No. 18, p. 8800-8811.
[cited by applicant]
Micksch, M. et al. “Synthesis of 1,2-Diaryl- and 1-Aryl-2-alkylimidazoles with Sterically Demanding Substituents”, Eur J. Org. Chem. 2013, Issue 27, p. 6137-6145.
[cited by applicant]
Miller III et al. “Design of e-pharmacophore models using compound fragments for the trans-sialidase of Trypanosoma cruzi: screening for novel inhibitor scaffolds”, Journal of Molecular Graphics and Modelling, vol. 45, …
[cited by applicant]
Mittur A. “Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders” Current Drug Therapy (2011), 6, pp. 17-34.
[cited by applicant]
Moradi-Afrapoli, F. et al. “In vitro α-glucosidase inhibitory activity of phenolic constituents from aerial parts of Polygonum hyrcanicum”, DARU Journal of Pharmaceutical Sciences, 2012, 20(1), 37, 6 pages.
[cited by applicant]
Motiwala, H. F. et al. “Remodeling and Enhancing Schmidt Reaction Pathways in Hexafluoroisopropanol”, J. Org. Chem. 2016, vol. 81, No. 8, p. 1593-1609.
[cited by applicant]
Nandi, A. et al. “Global Identification of O-GlcNAc-Modified Proteins”, Anal. Chem., 2006, 78, 452-458.
[cited by applicant]
Nelson, P. T. et al. “Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature”, J. Neuropathol. Exp. Neurol., 2012, 71(5), 362-381.
[cited by applicant]
Nettekoven, M. et al. “Synthetic Access to 2-Amido-5-aryl-8-methoxy-triazolopyridine and 2-Amido-5-morpholino-8-methoxy-triazolopyridine Derivatives as Potential Inhibitors of the Adenosine Receptor Subtypes”, Synthesis…
[cited by applicant]
Obach, R. S. “Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: and examination of in vitro half-life approach and nonspecific binding to microsomes”, Drug. Metab. Disp…
[cited by applicant]
Okamura, H. et al. “Rhodium-Catalyzed Imination of Sulfoxides and Sulfides: Efficient Preparation of N-Unsubstituted Sulfoximines and Sulfilimines”, Organic Letters, 2004, 6, 1305-1307.
[cited by applicant]
O'Mahony, G. E. et al. “Synthesis of enantioenriched sulfoxides” Arkivoc, 2011, 1-110.
[cited by applicant]
Orain, D. et al. “Synthesis of Orthogonally Protected 2,6-Diazaspiro[3.5]nonane and 2,6-Diazaspiro[3.4]octane Analogues as Versatile Building Blocks in Medicinal Chemistry”, Synlett, 2015, 26(13), 1815-1818.
[cited by applicant]
Papillon, J. P. N. et al. “Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects”, J. Med. Chem…
[cited by applicant]
Park, M.-J. et al. “High Glucose-induced O-GlcNAcylated Carbohydrate Response Element-binding Protein (ChREBP) Mediates Mesangial Cell Lipogenesis and Fibrosis”, J. Biol. Chem., 2014, 289, 13519-13530.
[cited by applicant]
Reddy et al. “Synthesis of Chiral Benzimidazole-Pyrrolidine Derivatives and their Application in Organocatalytic Aldol and Michael Addition Reactions”, Synthetic Communications, vol. 37, No. 24, 2007, pp. 4289-4299.
[cited by applicant]
Rouhi, A. M. et al. “The Right Stuff: From Research and Development to the Clinic, Getting Drug Crystals Right is Full of Pitfalls.” Chem. Eng. News. (2003):32-35.
[cited by applicant]
Ryan et al. “The O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease”, ACS Chemical Neuroscience, 2019, 17 pages.
[cited by applicant]
SantaCruz, K. et al. “Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function”, Science, 2005, 309, 476-481.
[cited by applicant]
Serajuddin, A. T. M. “Salt formation to improve drug solubility”, Advanced Drug Delivery Reviews, 2007, 59(7), 603-616.
[cited by applicant]
Shan, X. et al. “Reduced protein O-glycosylation in the nervous system of the mutant SOD1 transgenic mouse model of amyotrophic lateral sclerosis”, Neuroscience Letters, 2012, 516, 296-301.
[cited by applicant]
Shen, Q. et al. “Hydroxycoumarin Derivatives: Novel and Potent α-Glucosidase Inhibitors”, J. Med. Chem., 2010, 53(23), 8252-8259.
[cited by applicant]
Shirude, P. et al. “Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents”, J. Med. Chem., 2014, 57(13), 5728-5737.
[cited by applicant]
Sippy, K. B. et al. “Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors”, Bioorganic & Med. Chemistry Letters, 2009, 19(6), 1682-1685.
[cited by applicant]
Skedelj, V. et al. “Discovery of the first inhibitors of bacterial enzyme D-aspartate ligase from Enterococcus faecium (As1
[cited by applicant]
Silverman, “Prodrugs and Drug Delivery Systems”, The Organic Chemistry of Drug Design and Drug Action, (1992), Chapter 8, p. 352-399.
[cited by applicant]
Song, S. et al. “Efficient and Practical Oxidative Bromination and Iodination of Arenes and Heteroarenes with DMSO and Hydrogen Halide: A Mild Protocol for Late-Stage Functionalization”, Org. Lett., 2015, 17(12), 2886-2…
[cited by applicant]
Sperling, R. A. et al. “Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's dis…
[cited by applicant]
Spillantini, M. G.; Goedert, M. “Tau pathology and neurodegeneration”, Lancet Neurol., 2013, 12, 609-622.
[cited by applicant]
Tamura, B. K. et al. “Weight Loss in Patients with Alzheimer's Disease” J. Nutrition for the Elderly (2008), 26(3-4), pp. 21-38.
[cited by applicant]
Tan, H. et al. “Rational Screening Approach for Classical Chiral Resolution under Thermodynamic Equilibrium: A Case Study of Diphenyl-Substituted N-Methyl-Piperazine”, Organic Process Research and Development, 2011, 15(…
[cited by applicant]
Tanuwidjaja, J. et al. “One-Pot Asymmetric Synthesis of Either Diastereomer of tert-Butanesulfinyl-protected Amines from Ketones”, J. Org. Chem. 2007, 72, 626-629.
[cited by applicant]
The U. S. Pharmacopeia 38—National Formulary 35 Chapter 941, Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD) Official May 1, 2015, 427-431.
[cited by applicant]
Thiel, O. R. et al. “Practical Synthesis of a Vanilloid Receptor-1 Antagonist” J. Org. Chem., (2008), 73(9), pp. 3508-3515.
[cited by applicant]
Trapannone, R. et al. “O-GlcNAc transferase inhibitors: current tools and future challenges”, Biochemical Society Transactions, 2016, 44(1), 88-93.
[cited by applicant]
Vasudevan, A. et al. “Identification of aminopiperidine benzamides as MCHr1 antagonists”, Bioorganic & Medicinal Chemistry Letters, 2005, 15(14), 3412-3416.
[cited by applicant]
Volpe, D. A. “Application of Method Suitability for Drug Permeability Classification”, The AAPS Journal, 2010, 12(4), 670-678.
[cited by applicant]
Wall, G. M. “Pharmaceutical Applications of Drug Crystal Studies”, Pharm. Manuf., 1986, 3, 32-42.
[cited by applicant]
Wang, Z. et al. “Enrichment and Site Mapping of O-Linked N-Acetylglucosamine by a Combination of Chemical/Enzymatic Tagging, Photochemical Cleavage, and Electron Transfer Dissociation Mass Spectrometry”, Mol. Cell Prote…
[cited by applicant]
Waterman, K. C. “Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid Dosage Forms”, Pharm. Res., 2007, 24(4), 780-790.
[cited by applicant]
Weinberg, K. et al. “Synthesis and differential functionalisation of pyrrolidine and piperidine based spirodiamine scaffolds”, Tetrahedron, 2013, 69(23), 4694-4707.
[cited by applicant]
Wermuth, C. G. et al. “Designing Prodrugs and Bioprecursors I: Carrier Prodrugs”, The Practice of Medicinal Chemistry: Chapter 31, Academic Press, 1996, 671-696.
[cited by applicant]
Wiessner et al. “A novel non-carbohydrate o-linked beta-n-acetylglucosaminidase inhibitor increases tau o-glcnacylation In vivo”, Abstracts of the Annual Meeting of the Society for Neuroscience, Society for Neuroscience…
[cited by applicant]
Williams, D. R. et al. “Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome”, Brain, 2007, 130, 1566-1576.
[cited by applicant]
Xu, Daqian et al. “The synthesis of chiral tridentate ligands from L-proline and their application in the copper(II)-catalyzed enantioselective Henry reaction”, Tetrahedron Asymmetry, vol. 28, No. 7, 2017, p. 954-963.
[cited by applicant]
Hiroshi Yamanaka, Hiroshi Miyazaki and Naomi chi Murakami, Chemical Abstract, “Separation of optical isomers”, Japan, Gakkai Shopping Santa, 1989, 21 pages.
[cited by applicant]
Yoshida, M. et al. “Study of biodegradable copoly(L-lactic acid/glycolic acid) formulations with controlled release of Z-100 for application in radiation therapy”, Int. J. Pharm., 1995, 115, 61-67.
[cited by applicant]
Youngdale et al. “Synthesis and pharmacological activity of 3-(2-pyrrolidinyl)indoles”, Journal of Medicinal Chemistry, vol. 7, Jul. 1, 1964, pp. 415-427.
[cited by applicant]
Yu, Y. J. et al. “One-Pot Synthesis of Spirocyclic or Fused Pyrazoles from Cyclic Ketones: Calcium Carbide as the Carbon Source in Ring Expansion”, Org. Chem. 2017, vol. 82, No. 18, p. 9479-9486.
[cited by applicant]
Yuzwa, S. A. et al. “Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody”, Amino Acids, 2011, 40, 857-868.
[cited by applicant]
Yuzwa, S. A. et al. “A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo”, Nat. Chem. Biol., 2008, 4(8), 483-490.
[cited by applicant]
Yuzwa et al. “O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond”, Chem. Soc. Review, 2014, 20 pages.
[cited by applicant]
Yuzwa, S. A. et al. “Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation”, Nat. Chem. Biol., 2012, 8(4), 393-399.
[cited by applicant]
Zenzola, M. et al. “Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides”, Angew. Chem. Int. Ed., 2016, 55, 7203-7207.
[cited by applicant]
Zhang, Chen et al. “Nontraditional Reactions of Azomethine Ylides: Decarboxylative Three-Component Couplings of [alpha]-Amino Acids”, Journal of the American Chemical Society, vol. 132, No. 6, 2010, pp. 1798-1799.
[cited by applicant]
Addis et al., “Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector”. PloS one. Dec. 9, 2011; 6(12): 8 pages.
[cited by applicant]
Alenghat T. et al., “Histone deacetylase 3 coordinates commensal bacteria-dependent intestinal homeostasis”, (2013) Nature 504:153-157.
[cited by applicant]
Boxer AL et al., “Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial”, Lancet Neurol. 2014; 13(7): 676-85.
[cited by applicant]
Boxer et al., “Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.”, Lancet 16: 552-563, 2017.
[cited by applicant]
Chen YJ et al., “Protective Effects of Glucosamine on Oxidative-Stress and Ischemia/Reperfusion-Induced Retinal Injury”, (2015), Invest Ophthalmol. Vis Sci. 56(3): 1506-1516.
[cited by applicant]
Co-pending U.S. Appl. No. 18/570,861, inventors Beher; Dirk et al., filed on Dec. 15, 2023.
[cited by applicant]
Fleming et al., “Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human alpha-Synuclein”, 2004, The Journal of Neuroscience, 24 (42): 9434-40.
[cited by applicant]
Gilbert S. et al., “Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation”, (2012) EMBO Mol. Med.4: 109-124.
[cited by applicant]
Han OW et al., “Direct Reprogramming of Fibroblasts into Neural Stem Cells by Defined Factors”, (2012) Cell Stem Cell 10: 465-472.
[cited by applicant]
Hinz et al., “Molecular Genetics of Neurodegenerative Dementias”, Cold Spring Harbor Perspectives in Biology, 2017, 9:a023705 23 pages.
[cited by applicant]
Höglinger et al., “Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy”, Nature Genetics 43 :699-705, 2011.
[cited by applicant]
Höglinger GU et al., (2017) “Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials”, Movement Disorders, 32(6): 842-52.
[cited by applicant]
Höglinger GU et al., (2017) “Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria”, Movement Disorders, 32: 853-64.
[cited by applicant]
Kim J. et al., “Direct reprogramming of mouse fibroblasts to neural progenitors”, (2011) Proc Natl Acad Sci USA 108(19) :7838-7843.
[cited by applicant]
Kuhn J. et al. “Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's Dementia”, (2015) Brain Stimulation 8: 838-839.
[cited by applicant]
Levine PM. et al., (2019) “α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease”, Proc. Natl. Acad. Sci. USA 116(5):1511-1519.
[cited by applicant]
Lim MS. et al., “Generation of Dopamine Neurons from Rodent Fibroblasts through the Expandable Neural Precursor Cell Stage”, (2015) J. Biol. Chem. 290: 17401-17414.
[cited by applicant]
Lozano AM et al., (2016) “A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease”, Journal of Alzheimer's Disease, 54 : 777-787.
[cited by applicant]
Lujan E. et al., “Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells”, (2012) Proc Natl Acad Sci USA 109 : 2527-2532.
[cited by applicant]
Matsui T. et al., “Neural Stem Cells Directly Differentiated from Partially Reprogrammed Fibroblasts Rapidly Acquire Gliogenic Competency”, (2012) Stem Cells 30: 1109-1119.
[cited by applicant]
Mayer, Paul “On the Staining of Mucus”, (1896), Mitt. zool. Stn. Neape., 12, pp. 303-330.
[cited by applicant]
Mirzadeh Z. et al., “The rationale for deep brain stimulation in Alzheimer's disease”, (2016) J. Neural Transm (Vienna) 123: 775-783.
[cited by applicant]
Opposition Arguments, Notice of Opposition, Indian Pharmaceutical Alliance, in Patent Application No. 202127010343 dated Nov. 3, 2021 filed by Asceneuron S.A. (Applicant), dated Feb. 6, 2024, 26 pages.
[cited by applicant]
Paul S. et al., “Evaluation of a PET Radioligand to Image O-GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse”, J. Nucl. Med. 2019, 60(1), 129-134.
[cited by applicant]
Racine R.J., (1972) “Modification of Seizure Activity by Electrical Stimulation: I. After-Discharge Threshold”, Electroencephalography and Clinical Neurophysiology 32(3), 269-279.
[cited by applicant]
Rockenstein E, et al., “Differential Neuropathological Alterations in Transgenic Mice Expressing alpha-synuclein From the Platelet-derived Growth Factor and Thy-1 Promoters”, Journal of Neuroscience Research 68: 568-578…
[cited by applicant]
Sanchez et al., “Human and rodent temporal lobe epilepsy is characterized by changes in OGlcNAc homeostasis that can be reversed to dampen epileptiform activity”, (2019) Neurobiology of Disease 124: 531-543.
[cited by applicant]
Sankar T et al., “Deep Brain Stimulation Influences Brain Structure in Alzheimer's Disease”, (2015) Brain Stimulation 8: 645-654.
[cited by applicant]
Sheng C. et al., “Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors” (2012) Cell Res 22: 208-218.
[cited by applicant]
Stamelou M et al., (2016) “Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy”, Mov Disord. 31 (5): 742-7.
[cited by applicant]
Tolosa et al., (2014) “A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy”, Movement Disorders 29(4): 470-478.
[cited by applicant]
Vierbuchen et al., “Direct conversion of fibroblasts to functional neurons by defined factors”, (2010) Nature 463: 1035-1041.
[cited by applicant]
Wahlund et al., (2001) “A new rating scale for age-related white matter changes applicable to MRI and CT”, Stroke, 32(6):1318-1322.
[cited by applicant]
Zhang SZ. et al., “Modeling Neurological Disease by Rapid Conversion of Human Urine Cells into Functional Neurons”, (2016) Stem Cells International, 2016: 2452985.
[cited by applicant]
Zhao J. et al., “Neuronal Transcription Factors Induce Conversion of Human Glioma Cells to Neurons and Inhibit Tumorigenesis”, (2012) PLoS ONE7:5e41506.
[cited by applicant]
Zhao M, et al., “Deficiency in intestinal epithelial O-GlcNAcylation predisposes to gut inflammation”, (2018) EMBO Mol. Med. 10: 18 pages.
[cited by applicant]
CAS Registry Entry: 890335-15-6 (STN data summary sheet). Entered STN: Jul. 3, 2006, 1 pg.
[cited by applicant]
Cited By (1)